Working… Menu
Trial record 9 of 12 for:    MECLIZINE


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03586817
Recruitment Status : Unknown
Verified March 2019 by Estevão Braga, Hospital Federal de Bonsucesso.
Recruitment status was:  Recruiting
First Posted : July 16, 2018
Last Update Posted : March 12, 2019
Information provided by (Responsible Party):
Estevão Braga, Hospital Federal de Bonsucesso

Brief Summary:

Cholelithiasis (presence of gallbladder stones) is prevalent in 10 to 15% of the world population. This disease can lead to serious complications such as cholecystitis, cholangitis and pancreatitis. Video-laparoscopic cholecystectomy (CVL) is considered the gold standard treatment of this condition.

Despite ongoing research and development of new drugs and techniques, postoperative nausea and vomiting (PONV) are frequent, lead to unexpected hospitalizations, delay hospital discharge, increase hospital costs, and cause patient dissatisfaction. Video-laparoscopic surgeries are cited in the literature as a risk factor for PONV, with an incidence of up to 75% in cases where prophylactic drugs are not used.Through the simplified Apfel score, it is possible to determine the risk for PONV. This risk classification is based on four risk factors: female gender, non-smoking, postoperative use of opioids and previous history of PONV. The incidence of PONV would be 10%, 20%, 40%, 60% and 80%, respectively, if none, one, two, three or four risk factors are present.

Antiemetics recommended for prophylaxis of PONV in adults include 5-hydroxytryptamine (5-HT3) receptor antagonists (ondansetron, dolasetron, granisetron, tropisetron, ramosetron and palonosetron), neurokinin-1 (NK-1) receptor antagonists (aprepitant), (dendrohydrin and haloperidol), antihistamines (dimenhydrin and meclizine), and anticholinergics (scopolamine).

Condition or disease Intervention/treatment Phase
Nausea and Vomiting, Postoperative Drug: Palonosetron Drug: Fosaprepitant Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Estimated Study Start Date : March 2, 2019
Actual Primary Completion Date : March 2, 2019
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Palonosetrona
Palonosetron 75 mcg during the anesthesia
Drug: Palonosetron
75 mcg during the anesthesia

Active Comparator: Fosaprepitant
Fosaprepitant 150 mg during the anesthesia
Drug: Fosaprepitant
150 mg during the anesthesia

Primary Outcome Measures :
  1. Number of complete responder [ Time Frame: 48 hours ]
    individuals without nausea or vomiting

Secondary Outcome Measures :
  1. Nausea [ Time Frame: the first postoperative 48 hours ]
    questionnaire on the number of individual episodes of nausea

  2. vomiting [ Time Frame: the first postoperative 48 hours ]
    questionnaire on the number of individual episodes of vomiting

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Fenale
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women
  • Non fumant
  • cholelitiasis

Exclusion Criteria:

  • severe heart, pulmonay, renal or liver diseases
  • Tabagism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03586817

Layout table for location information
Hospital Federal de Bonsucesso Recruiting
Rio de Janeiro, Brazil, 21041-030
Contact: Estêvão LC Braga, Md    5521998549109   
Contact: Ismar L Cavalcanti, PhD    5521999822993   
Sub-Investigator: Núbia Verçosa, PhD         
Sponsors and Collaborators
Hospital Federal de Bonsucesso
Layout table for additonal information
Responsible Party: Estevão Braga, Clinical Professor, Hospital Federal de Bonsucesso Identifier: NCT03586817    
Other Study ID Numbers: 89510518.6.0000.5253
First Posted: July 16, 2018    Key Record Dates
Last Update Posted: March 12, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Postoperative Nausea and Vomiting
Signs and Symptoms, Digestive
Postoperative Complications
Pathologic Processes
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin 5-HT3 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurokinin-1 Receptor Antagonists